Toggle Main Menu Toggle Search

Open Access padlockePrints

Adaptive dosing and platinum-DNA adduct formation in children receiving high-dose carboplatin for the treatment of solid tumours

Lookup NU author(s): Professor Gareth Veal, Julie Errington, Dr Michael Tilby, Professor Alan Boddy


Full text for this publication is not currently held within this repository. Alternative links are provided below where available.


A pharmacokinetic-pharmacodynamic study was carried out to investigate the feasibility and potential importance of therapeutic monitoring following high-dose carboplatin treatment in children. High-dose carboplatin was administered over 3 or 5 days, with the initial dose based on renal function, to achieve target area under the plasma concentration-time curve (AUC) values of 21 or 20 mg ml-1.min, respectively. Dose adjustment was carried out based on observed individual daily AUC values, to obtain the defined target exposures. Platinum-DNA adduct levels were determined in peripheral blood leucocytes and toxicity data were obtained. Twenty-eight children were studied. Based on observed AUC values, carboplatin dose adjustment was performed in 75% (21 out of 28) patients. Therapeutic monitoring resulted in the achievement of carboplatin exposures within 80-126% of target AUC values, as compared to estimated exposures of 65-213% of target values without dose adjustment. The carboplatin AUC predicted with no dose modification was positively correlated with pretreatment glomerular filtration rate (GFR) values. Higher GFR values were observed in those patients who would have experienced AUC values >25% above the target AUC than those patients attaining AUC values >25% below the target AUC, following renal function-based dosing. Platinum-DNA adduct levels correlated with observed AUC values on day 1 of carboplatin and increased over a 5-day course of treatment. Real-time monitoring of carboplatin pharmacokinetics with adaptive dosing is both feasible and necessary for the attainment of consistent AUC values in children receiving high-dose carboplatin treatment. Pharmacodynamic data suggest a strong correlation between carboplatin pharmacokinetics and the drug-target interaction. © 2007 Cancer Research.

Publication metadata

Author(s): Veal GJ, Errington J, Tilby MJ, Pearson ADJ, Foot A, McDowell H, Ellershaw C, Pizer B, Nowell G, Pearson D, Boddy AV

Publication type: Article

Publication status: Published

Journal: British Journal of Cancer

Year: 2007

Volume: 96

Issue: 5

Pages: 725-731

Print publication date: 12/03/2007

ISSN (print): 0007-0920

ISSN (electronic): 1532-1827

Publisher: Nature Publishing Group


DOI: 10.1038/sj.bjc.6603607

PubMed id: 17299395


Altmetrics provided by Altmetric


Funder referenceFunder name
EP/C509005/1Engineering and Physical Sciences Research Council